Table 1.
Characteristics of the included trials.
| Study (Year) | Study type | Cancer type/Chemotherapy regimen | Experimental/Control arm (No.) | Outcomes | Quality scores |
|---|---|---|---|---|---|
| Ng et al. (16) | RCT | Breast cancer/paclitaxel | Frozen gloves and socks on all extremities/no (17/21) | PNQ grade ≥D for sensory and motor peripheral neuropathy | 5/7 |
| Ruddy et al. (17) | RCT | Breast cancer/paclitaxel | Cryotherapy/standard therapy (21/21) | CTCAE grade ≥2 for sensory peripheral neuropathy | 3/7 |
| Shigematsu et al. (18) | RCT | Breast cancer/paclitaxel | Frozen gloves and socks/no (22/22) | CTCAE grade ≥2 and PNQ grade ≥D for sensory and motor peripheral neuropathy | 4/7 |
| Bandla et al. (19) | nRCT | Breast cancer/paclitaxel; Prostate cancer/docetaxel |
Four-limb cryocompression and continuous-flow cooling/control (34/21) | Nerve conduction studies | 16/24 |
| Eckhoff et al. (10) | nRCT | Breast Cancer/docetaxel | Frozen gloves and socks/no (686/862) | CTCAE grade ≥2 for sensory peripheral neuropathy | 17/24 |
| Hanai et al. (20) | nRCT | Breast cancer/paclitaxel | Frozen gloves and socks on the dominant side/untreated sides (36/36) | PNQ grade ≥D for sensory peripheral neuropathy | 20/24 |
| Rosenbaek et al. (21) | nRCT | Breast cancer/paclitaxel | Prophylactic cryotherapy/therapeutic cryotherapy (96/119) | Dose reduction due to TIPN | 16/24 |
| Sato et al. (22) | nRCT | Gynecologic cancer/paclitaxel | Regional cooling/control (40/142) | Dose reduction due to PN | 16/24 |
| Shimanuki et al. (23) | nRCT | Early-stage breast cancer/paclitaxel | Cryotherapy applied to both hands and feet/no cryotherapy (26/64) | CTCAE grade ≥2 for sensory peripheral neuropathy, dose reduction due to PN | 21/24 |